Halozyme to restructure after failure of pivotal pancreatic cancer study
The biotech company will shut down its development program for PEGPH20 and instead focus on its drug delivery technology program while laying off 55 percent of its workforce.
The biotech company will shut down its development program for PEGPH20 and instead focus on its drug delivery technology program while laying off 55 percent of its workforce.